GB201103167D0 - Gene silencing - Google Patents
Gene silencingInfo
- Publication number
- GB201103167D0 GB201103167D0 GB201103167A GB201103167A GB201103167D0 GB 201103167 D0 GB201103167 D0 GB 201103167D0 GB 201103167 A GB201103167 A GB 201103167A GB 201103167 A GB201103167 A GB 201103167A GB 201103167 D0 GB201103167 D0 GB 201103167D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- gene
- interest
- pol
- promoter element
- dna molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention provides a method of reducing or preventing the expression of a gene of interest comprising providing a DNA molecule having a sequence which comprises in a 5' to 3' direction (i) a Pol II promoter element in sense orientation, (ii) the gene of interest or a portion thereof comprising 40 nucleotides or more, and (iii) a Pol II promoter element in antisense orientation, and expressing the gene of interest incorporated into the DNA molecule in a mammalian cell. It also provides a method of reducing or preventing the expression of a gene of interest in a mammalian cell comprising integrating a Pol II promoter element in antisense orientation downstream (3') of the gene of interest and inducing expression from the antisense promoter. It also provides an in vitro method of preparing a pool of siRNA molecules specific for a gene of interest comprising providing a DNA molecule having a sequence which comprises in a 5' to 3' direction (i) a Pol II promoter element in sense orientation, (ii) the gene of interest or a portion thereof comprising 100 nucleotides or more, and (iii) a Pol II promoter element in antisense orientation, and transcribing the gene of interest in the presence of Dicer, preferably recombinant Dicer, to produce siRNA molecules.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201103167A GB201103167D0 (en) | 2011-02-24 | 2011-02-24 | Gene silencing |
PCT/GB2012/050410 WO2012114111A1 (en) | 2011-02-24 | 2012-02-23 | Gene silencing |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201103167A GB201103167D0 (en) | 2011-02-24 | 2011-02-24 | Gene silencing |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201103167D0 true GB201103167D0 (en) | 2011-04-06 |
Family
ID=43881589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB201103167A Ceased GB201103167D0 (en) | 2011-02-24 | 2011-02-24 | Gene silencing |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201103167D0 (en) |
WO (1) | WO2012114111A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014337506B2 (en) * | 2013-10-14 | 2020-10-15 | Ionis Pharmaceuticals, Inc. | Methods for modulating expression of C9ORF72 antisense transcript |
WO2015057727A1 (en) * | 2013-10-14 | 2015-04-23 | Isis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001077350A2 (en) | 2000-04-07 | 2001-10-18 | Large Scale Biology Corporation | Compositions and methods for inhibiting gene expression |
CA2501065A1 (en) * | 2002-09-04 | 2004-03-18 | Johnson & Johnson Research Pty Ltd | Methods using dsdna to mediate rna interference (rnai) |
US20050060771A1 (en) * | 2003-09-11 | 2005-03-17 | Farmer Andrew Alan | siRNA encoding constructs and methods for using the same |
US7713735B2 (en) * | 2004-09-24 | 2010-05-11 | J.R. Simplot Company | Gene silencing |
EP2208785A1 (en) * | 2009-01-15 | 2010-07-21 | Newbiotechnic, S.A. | Methods and kits to generate miRNA- and smallRNA-expressing vectors, and its application to develop lentiviral expression libraries |
-
2011
- 2011-02-24 GB GB201103167A patent/GB201103167D0/en not_active Ceased
-
2012
- 2012-02-23 WO PCT/GB2012/050410 patent/WO2012114111A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2012114111A1 (en) | 2012-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Shapiro et al. | Evidence for a cytoplasmic microprocessor of pri-miRNAs | |
MX358706B (en) | Artificial nucleic acid molecules comprising a 5'top utr. | |
MX2019002345A (en) | Artificial nucleic acid molecules for improved protein or peptide expression. | |
MX357803B (en) | Artificial nucleic acid molecules. | |
WO2006135436A3 (en) | Inhibition of gene expression and therapeutic uses thereof | |
EA024762B9 (en) | Compositions and methods for inhibiting gene expression of hepatitis b virus | |
MX2023000053A (en) | Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof. | |
MX2013003681A (en) | Engineered nucleic acids and methods of use thereof. | |
SG195194A1 (en) | Nanogels | |
BRPI0819526B8 (en) | ARTIFICIAL MIRNA PRECURSOR NUCLEIC ACID SEQUENCE, RECOMBINANT CONSTRUCTION AND METHOD FOR REDUCING EXPRESSION OF A TARGET SEQUENCE | |
WO2008156702A3 (en) | Bacteria mediated gene silencing | |
WO2011038160A3 (en) | Compositions and methods for silencing genes expressed in cancer | |
WO2012046085A3 (en) | Methods of inducing insulin production | |
NZ609903A (en) | Expression vector for high level expression of recombinant proteins | |
GB201103167D0 (en) | Gene silencing | |
Duan et al. | Bioengineered non-coding RNA agent (BERA) in action | |
DE502006002711D1 (en) | REPLICATION-DEFICIENT RNA VIRUSES AS VACCINES | |
WO2011114106A3 (en) | Gene silencing | |
IN2014CN03921A (en) | ||
WO2005086896A3 (en) | Delivery vectors for short interfering rna, micro-rna and antisense rna | |
EP3112465A3 (en) | Method for identification and isolation of terminator sequences causing enhanced transcription | |
WO2010081842A3 (en) | METHODS AND KITS TO GENERATE miRNA- AND small RNA-EXPRESSING VECTORS, AND ITS APPLICATION TO DEVELOP LENTIVIRAL EXPRESSION LIBRARIES | |
WO2013046216A3 (en) | Two plasmid mammalian expression system | |
WO2011054939A3 (en) | Compositions and methods for inhibiting expression of kif10 genes | |
RU2013148804A (en) | METHOD FOR PRODUCING RECOMBINANT POLYPEPTIDE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |